Quick Answer
Topical metformin 1% gel is being studied as an adjunct to scaling and root planing (SRP) for periodontitis. A 2025 systematic review found that locally delivered 1% metformin gel used with SRP was associated with improvements in periodontal pocket depth, clinical attachment level, and intrabony defect measurements. The evidence is promising, but larger independent clinical trials are still needed.
Key Takeaways
Topical metformin 1% gel has been studied as an adjunct to scaling and root planing for periodontitis.
Research suggests potential effects on inflammation, bone remodeling, and periodontal healing.
A 2025 meta-analysis reported improvements in probing pocket depth, clinical attachment level, and intrabony defects when metformin gel was added to SRP.
The published evidence does not establish a standardized repeat-application schedule.
Compounded metformin gel for periodontal use is not FDA-approved for this indication and should be prescribed based on the individual patient and the clinician’s judgment.
Topical Metformin 1% Gel for Periodontitis: An Emerging Adjunct to Scaling and Root Planing
Topical metformin 1% gel is an emerging adjunctive therapy for periodontitis, a chronic inflammatory disease that damages the tissues and bone supporting the teeth. Unlike locally delivered antibiotics such as Arestin® (minocycline hydrochloride), metformin is being investigated for its potential to modulate inflammation and bone remodeling. A 2025 systematic review and meta-analysis of six studies found that adding locally delivered 1% metformin gel to scaling and root planing (SRP) was associated with improvements in periodontal pocket depth, clinical attachment level, and intrabony defect measurements at three and six months. These findings are promising but require confirmation through larger, independent clinical trials. Healing Dose Compounding Pharmacy offers patient-specific compounded metformin 1% gel for prescribers considering this emerging approach to periodontal care.
What Is Metformin 1% Gel for Periodontitis?
Periodontitis is a chronic inflammatory condition in which bacterial biofilm triggers tissue destruction, periodontal pocket formation, and loss of supporting alveolar bone. Scaling and root planing (SRP) is a foundational nonsurgical treatment that removes plaque and calculus from below the gumline.
Researchers are investigating locally delivered metformin gel as an adjunct to SRP to help address the inflammatory and bone-remodeling processes involved in periodontal damage.
Metformin is traditionally used to manage type 2 diabetes. In periodontal research, its potential role differs from that of Arestin, which delivers the antibiotic minocycline directly into periodontal pockets. Metformin is being studied primarily for its potential host-modulating effects.
How Does Metformin Work in Periodontal Therapy?
Research suggests that metformin may influence several processes relevant to periodontal health:
- Inflammation: May modulate inflammatory signaling associated with periodontal tissue injury.
- Bone remodeling: Laboratory studies suggest metformin may inhibit osteoclast formation and activity, potentially affecting the bone-resorption process.
- Periodontal healing: Clinical studies have reported improvements in pocket depth, clinical attachment, and intrabony defect measurements when metformin gel is used with SRP.
These mechanisms provide a scientific rationale for further investigation, but the precise contribution of each pathway to clinical outcomes remains under study.
What Does the Clinical Evidence Show?
A 2025 systematic review and meta-analysis by Haba et al. evaluated six studies of locally delivered 1% metformin gel. Compared with SRP plus placebo, SRP plus metformin was associated with the following additional improvements:
| Periodontal Measurement | 3 Months | 6 Months |
|---|---|---|
| Probing pocket depth | 1.33 mm | 1.87 mm |
| Clinical attachment level | 1.80 mm | 2.14 mm |
| Intrabony defect depth | — | 1.16 mm |
These pooled estimates represent differences between treatment and control groups, not the expected change for every patient. The review supports further study of metformin 1% gel as an adjunct to conventional periodontal treatment. However, the small evidence base and need for independent trials limit the conclusions that can be drawn.
How Does Metformin Compare With Arestin?
Arestin is a locally administered minocycline antibiotic used alongside SRP. In two pivotal clinical trials involving 748 adults, mean probing-depth reductions at nine months were 1.18 mm with SRP alone and 1.42 mm with SRP plus Arestin—a 0.24 mm difference.
The metformin findings and Arestin results come from separate studies with different populations, protocols, and follow-up periods. They are not a head-to-head comparison and do not establish that one treatment is superior to the other.
Application, Frequency, and Follow-Up
Published studies evaluated metformin gel placed subgingivally at selected periodontal sites, generally in conjunction with SRP.
- Concentration: 1% is the concentration evaluated in the 2025 systematic review and meta-analysis.
- Application: The treating dental professional places the gel directly into selected periodontal pockets according to the prescribed protocol.
- Frequency: The literature does not establish a standardized repeat-application schedule. Routine reapplication every three to four months has not been established by the published evidence.
- Follow-up: Clinical outcomes have been assessed at intervals including three and six months. These are study assessment points, not automatic redosing recommendations.
The treating clinician should determine the application protocol and any repeat treatment based on the patient’s periodontal condition and clinical needs.
Metformin 1% Gel Through Healing Dose Compounding Pharmacy
Healing Dose Compounding Pharmacy works with prescribers to provide patient-specific compounded metformin 1% gel for consideration as an adjunct to periodontal therapy.
Prescribers can contact the pharmacy to discuss prescription requirements, formulation considerations, dispensing information, and patient-specific availability.
Important Compounding Disclaimer
Metformin gel compounded for periodontal use is not FDA-approved for this indication. Compounded drugs are not reviewed by the FDA for safety, effectiveness, or quality before marketing. Use should be based on the prescriber’s independent clinical judgment, applicable compounding requirements, and the individual patient’s needs.
References:
- Haba KS, et al. (2025). Locally delivered 1% metformin gel improves periodontal parameters: A systematic review and meta-analysis. The Saudi Dental Journal, 37, 40. Read the study.
- Pradeep AR, et al. (2013). Efficacy of varying concentrations of subgingivally delivered metformin in the treatment of chronic periodontitis. Journal of Periodontology, 84(2), 212–220. Read the study.
- Pradeep AR, et al. (2016). Efficacy of locally delivered 1% metformin gel in the treatment of intrabony defects in patients with chronic periodontitis. Journal of Investigative and Clinical Dentistry, 7(3), 239–245. Read the study.
- Tao LY, et al. (2022). Diabetes medication metformin inhibits osteoclast formation and activity in in vitro models for periodontitis. Frontiers in Cell and Developmental Biology, 9, 777450. Read the study.
- Arestin® (minocycline hydrochloride) prescribing information. DailyMed.
